Patents by Inventor Adel M. Moussa

Adel M. Moussa has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ENANTIOMERICALLY PURE PHOSPHOINDOLES AS HIV INHIBITORS
    Publication number: 20110257129
    Abstract: 3-phosphoindole compounds substantially in the form of a single enantiomer useful for the treatment of Flaviviridae virus infections, and particularly for HIV infections are provided. Also provided are pharmaceutical compositions comprising the 3-phosphoindole compounds alone or in combination with one or more other anti-viral agents, processes for their preparation, and methods of manufacturing a medicament incorporating these compounds.
    Type: Application
    Filed: June 2, 2011
    Publication date: October 20, 2011
    Inventors: Richard Storer, Francois-Rene Alexandre, Cyril Dousson, Adel M. Moussa, Edward Bridges, Alistair Stewart, Jing Yang Wang, Benjamin Alexander Mayes
  • Enantiomerically pure phosphoindoles as HIV inhibitors
    Patent number: 7960428
    Abstract: 3-phosphoindole compounds substantially in the form of a single enantiomer useful for the treatment of Flaviviridae virus infections, and particularly for HIV infections are provided. Also provided are pharmaceutical compositions comprising the 3-phosphoindole compounds alone or in combination with one or more other anti-viral agents, processes for their preparation, and methods of manufacturing a medicament incorporating these compounds.
    Type: Grant
    Filed: September 28, 2007
    Date of Patent: June 14, 2011
    Assignee: Idenix Pharmaceuticals, Inc.
    Inventors: Richard Storer, Francois-Rene Alexandre, Cyril Dousson, Adel M. Moussa, Edward Bridges, Alistair Stewart, Jing Yang Wang, Benjamin Alexander Mayes
  • SOLID FORMS OF AN ANTI-HIV PHOSPHOINDOLE COMPOUND
    Publication number: 20110039803
    Abstract: Solid forms comprising a compound useful in the treatment, prevention and management of various conditions and diseases are provided herein. In particular, provided herein are solid forms comprising (2-carbamoyl-5-chloro-1H-indol-3-yl)-[3-((E)-2-cyano-vinyl)-5-methyl-phenyl]-(R)-phosphinic acid methyl ester, including salts thereof, having utility for the treatment, prevention and management of conditions and disorders including, but not limited to, human immunodeficiency virus infection.
    Type: Application
    Filed: March 27, 2009
    Publication date: February 17, 2011
    Inventors: Adel M. Moussa, Mike H. O'Neill, Xiaohong Sheng
  • Process for the production of 2-C-methyl-D-ribonolactone
    Patent number: 7598373
    Abstract: The present invention provides an improved process for preparing 2-C-methyl-D-ribonolactone.
    Type: Grant
    Filed: December 12, 2003
    Date of Patent: October 6, 2009
    Assignee: Idenix Pharmaceuticals, Inc.
    Inventors: Richard Storer, Adel M. Moussa, Narayan Chaudhuri, Frank Waligora
  • Use of triaryl methane compounds for inhibiting unwanted cellular proliferation associated with inflammatory disease
    Patent number: 7531573
    Abstract: The present invention provides a class of chemical compounds useful as efficacious drugs in the treatment of sickle cell disease and diseases characterized by unwanted or abnormal cell proliferation, and in particular inflammatory diseases associated with unwanted cellular proliferation. The active compounds are substituted triaryl methane compounds or analogues thereof where one or more of the aryl groups is replaced with a heteroaryl, cycloalkyl or heterocycloalkyl group and/or the tertiary carbon atom is replaced with a different atom such as Si, Ge, N or P. the compounds inhibit mammalian cell proliferation, inhibit the Gardos channel of erythrocytes, reduce sickle erythrocyte dehydration and/or delay the occurrence of erythrocyte sickling or deformation.
    Type: Grant
    Filed: June 3, 2003
    Date of Patent: May 12, 2009
    Assignee: Children's Medical Center Corporation
    Inventors: Carlo Brugnara, Jose Halperin, Emile M. Bellot, Jr., Mark Froimowitz, Richard John Lombardy, John J. Clifford, Ying-Duo Gao, Reem M. Haidar, Eugene W. Kelleher, Falguni M. Kher, Adel M. Moussa, Yesh P. Sachdeva, Minghua Sun, Heather N. Taft
  • Enantiomerically pure phosphoindoles as HIV inhibitors
    Publication number: 20080213217
    Abstract: 3-phosphoindole compounds substantially in the form of a single enantiomer useful for the treatment of Flaviviridae virus infections, and particularly for HIV infections are provided. Also provided are pharmaceutical compositions comprising the 3-phosphoindole compounds alone or in combination with one or more other anti-viral agents, processes for their preparation, and methods of manufacturing a medicament incorporating these compounds.
    Type: Application
    Filed: September 28, 2007
    Publication date: September 4, 2008
    Inventors: Richard Storer, Francois-Rene Alexandre, Cyril Dousson, Adel M. Moussa, Edward Bridges, Alistair Stewart, Jing Yang Wang, Benjamin Alexander Mayes
  • Substituted diphenyl indanone, indane and indole compounds and analogues thereof useful for the treatment or prevention of diseases characterized by abnormal cell proliferation
    Patent number: 7342038
    Abstract: The present invention provides substituted 3,3-diphenyl indole compounds, as well as analogues thereof, which are specific potent and safe inhibitors of mammalian cell proliferation. The compounds can be used to inhibit mammalian cell proliferation in situ as a therapeutic approach towards the treatment or prevention of diseases characterized by abnormal cell proliferation, such as cancer.
    Type: Grant
    Filed: June 1, 2004
    Date of Patent: March 11, 2008
    Assignees: President and Fellow of Harvard College, Children's Medical Center Corporation, NuChem Pharmaceuticals Inc.
    Inventors: Carlo Brugnara, Jose Halperin, Rudolf Fluckiger, Emile M. Bellott, Jr., Richard John Lombardy, John J. Clifford, Ying-Duo Gao, Reem M. Haidar, Eugene W. Kelleher, Adel M. Moussa, Yesh P. Sachdeva, Minghua Sun, Heather N. Taft
  • Substituted 11-phenyl-dibenzazepine compounds useful for the treatment or prevention of diseases characterized by abnormal cell proliferation
    Patent number: 6992079
    Abstract: The present invention provides substituted 11-phenyl-dibenzazepine compounds which are specific, potent and safe inhibitors of mammalian cell proliferation. The compounds can be used to inhibit mammalian cell proliferation in situ as a therapeutic approach towards the treatment or prevention of diseases characterized by abnormal cell proliferation, such as cancer.
    Type: Grant
    Filed: December 7, 2001
    Date of Patent: January 31, 2006
    Assignees: President Fellows of Harvard College, Children's Medical Center Corporation, NuChem Pharmaceuticals Inc.
    Inventors: Carlo Brugnara, Jose Halperin, Rudolf Fluckiger, Emile M. Bellott, Jr., Richard John Lombardy, John J. Clifford, Ying-Duo Gao, Reem M. Haidar, Eugene W. Kelleher, Adel M. Moussa, Yesh P. Sachdeva, Minghua Sun, Heather N. Taft, Michael H. Zeldin
  • Substituted diphenyl indanone, indane and indole compounds and analogues thereof useful for the treatment or prevention of diseases characterized by abnormal cell proliferation
    Publication number: 20040242563
    Abstract: The present invention provides substituted 3,3-phenyl indanone, indane and indole compounds, as well as analogues thereof, which are specific, potent and safe inhibitors of mammalian cell proliferation. The compounds can be used to inhibit mammalian cell proliferation in situ as a therapeutic approach towards the treatment or prevention of diseases characterized by abnormal cell proliferation, such as cancer.
    Type: Application
    Filed: June 1, 2004
    Publication date: December 2, 2004
    Applicants: Children's Medical Center Corporation, President and Fellows of Harvard College, Nuchem Pharmaceuticals Inc.
    Inventors: Carlo Brugnara, Jose Halperin, Rudolf Fluckiger, Emile M. Bellott, Richard John Lombardy, John J. Clifford, Ying-Duo Gao, Reem M. Haidar, Eugene W. Kelleher, Adel M. Moussa, Yesh P. Sachdeva, Minghua Sun, Heather N. Taft
  • Substituted diphenyl indanone, indane and indole compounds and analogues thereof useful for the treatment of prevention of diseases characterized by abnormal cell proliferation
    Patent number: 6800658
    Abstract: The present invention provides substituted 3,3-diphenyl indanone, indane and indole compounds, as well as analogues thereof, which are specific, potent and safe inhibitors of mammalian cell proliferation. The compounds can be used to inhibit mammalian cell proliferation in situ as a therapeutic approach towards the treatment or prevention of diseases characterized by abnormal cell proliferation, such as cancer.
    Type: Grant
    Filed: January 10, 2002
    Date of Patent: October 5, 2004
    Assignees: Children's Medical Center Corporation, President & Fellows of Harvard College, Nuchem Pharmaceuticals, Inc.
    Inventors: Carlo Brugnara, Jose Halperin, Rudolf Fluckiger, Emile M. Bellott, Jr., Richard John Lombardy, John J. Clifford, Ying-Duo Gao, Reem M. Haidar, Eugene W. Kelleher, Adel M. Moussa, Yesh P. Sachdeva, Minghua Sun, Heather N. Taft
  • Process for the production of 3'-nucleoside prodrugs
    Publication number: 20040181051
    Abstract: Provided is a single-step process for the selective 3′-acylation of a ribofuranosyl 2′ or 3′-branched nucleoside. These compounds are useful as antiviral agents, and in particular, can be used to treat Flaviviridae infections in a host in need thereof.
    Type: Application
    Filed: December 23, 2003
    Publication date: September 16, 2004
    Inventors: Richard Storer, Adel M. Moussa, Steven Mathieu
  • Use of triaryl methane compounds for inhibiting unwanted cellular proliferation associated with inflammatory disease
    Publication number: 20040127464
    Abstract: The present invention provides a class of chemical compounds useful as efficacious drugs in the treatment of sickle cell disease and diseases characterized by unwanted or abnormal cell proliferation, and in particular inflammatory diseases associated with unwanted cellular proliferation. The active compounds are substituted triaryl methane compounds or analogues thereof where one or more of the aryl groups is replaced with a heteroaryl, cycloalkyl or heterocycloalkyl group and/or the tertiary carbon atom is replaced with a different atom such as Si, Ge, N or P. the compounds inhibit mammalian cell proliferation, inhibit the Gardos channel of erythrocytes, reduce sickle erythrocyte dehydration and/or delay the occurrence of erythrocyte sickling or deformation.
    Type: Application
    Filed: June 3, 2003
    Publication date: July 1, 2004
    Inventors: Carlo Brugnara, Jose Halperin, Emile M. Bellot, Mark Froimowitz, Richard John Lombardy, John J. Clifford, Ying-Duo Gao, Reem M. Haidar, Eugene W. Kelleher, Falguni M. Kher, Adel M. Moussa, Yesh P. Sachdeva, Minghua Sun, Heather N. Taft
  • Methods of separating FTC isomers and derivatives thereof
    Patent number: 6752929
    Abstract: The present invention relates to a method of preparing enantiomers and diastereomers of a 2′,3′-dideoxy-5-fluoro-3′thiocytadine (FTC) or a derivative thereof as represented by the structural formula (I), wherein R is H, a substituted or unsubstituted organic acid radical, a substituted or unsubstituted alkyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted heteroaryl group, a substituted or unsubstituted aralkyl group, a substituted or unsubstituted heteroarakyl group, a substituted or unsubstituted cycloalkyl group, a substituted or unsubstituted heterocycloalkyl group, a substituted or unsubstitued cycloalkylalkyl group, a substituted or unsubstituted heterocycloalkylalkyl group, a sugar or a protecting group.
    Type: Grant
    Filed: July 12, 2002
    Date of Patent: June 22, 2004
    Assignee: Johnson Matthey Pharmaceutical Materials, Inc.
    Inventors: Salah Zahr, David A. Swanson, Adel M. Moussa, Luning Han
  • Substituted 11-phenyl-dibenzazepine compounds useful for the treatment or prevention of diseases characterized by abnormal cell proliferation
    Publication number: 20040002486
    Abstract: The present invention provides substituted 11-phenyl-dibenzazepine compounds which are specific, potent and safe inhibitors of mammalian cell proliferation. The compounds can be used to inhibit mammalian cell proliferation in situ as a therapeutic approach towards the treatment or prevention of diseases characterized by abnormal cell proliferation, such as cancer.
    Type: Application
    Filed: December 7, 2001
    Publication date: January 1, 2004
    Inventors: Carlo Brugnara, Jose Halperin, Rudolf Fluckiger, Emile M. Bellott, Richard John Lombardy, John J. Clifford, Ying-Duo Gao, Reem M. Haidar, Eugene W. Kelleher, Adel M. Moussa, Yesh P. Sachdeva, Minghua Sun, Heather N. Taft, Michael H. Zeldin
  • Substituted 11-phenyl-dibenzazepine compounds useful for the treatment or prevention of diseases characterized by abnormal cell proliferation
    Publication number: 20030191111
    Abstract: The present invention provides substituted 11-phenyl-dibenzazepine compounds which are specific, potent and safe inhibitors of mammalian cell proliferation. The compounds can be used to inhibit mammalian cell proliferation in situ as a therapeutic approach towards the treatment or prevention of diseases characterized by abnormal cell proliferation, such as cancer.
    Type: Application
    Filed: January 21, 2003
    Publication date: October 9, 2003
    Applicant: CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Carlo Brugnara, Jose Halperin, Rudolf Fluckiger, Emile M. Bellott, Richard John Lombardy, John J. Clifford, Ying-Duo Gao, Reem M. Haidar, Eugene W. Kelleher, Adel M. Moussa, Yesh P. Sachdeva, Minghua Sun, Heather N. Taft, Michael H. Zeldin
  • METHODS FOR THE TREATMENT OR PREVENTION OF INFLAMMATORY DISEASES CHARACTERIZED BY ABNORMAL CELL PROLIFERATION
    Publication number: 20030134842
    Abstract: The present invention provides substituted 11-phenyl-dibenzazepine compounds which are specific, potent and safe inhibitors of the Ca2+-activated potassium channel (Gardos channel) of erythrocytes. The compounds can be used as efficacious drugs in the treatment of sickle cell disease and diseases characterized by unwanted or abnormal cell proliferation, and in particular inflammatory diseases associated with unwanted cellular proliferation.
    Type: Application
    Filed: September 23, 1998
    Publication date: July 17, 2003
    Inventors: CARLO BRUGNARA, JOSE HALPERIN, EMILE M. BELLOT JR, MARK FROIMOWITZ, RICHARD JOHN LOMBARDY, JOHN J. CLIFFORD, YING-DUO GAO, REEM M. HAIDER, EUGENE W. KELLEHER, FALGUNI M. KHER, ADEL M. MOUSSA, YESH P. SACHDEVA, MINGHUA SUN, HEATHER N. TAFT
  • Methods of separating FTC isomers and derivatives thereof
    Patent number: 6541631
    Abstract: The present invention relates to a method of preparing enantiomers and diastereomers of a 2′,3′-dideoxy-5-fluoro-3′thiocytadine (FTC) or a derivative thereof as represented by the following structural formula: In Structural Formula I, R is H, a substituted or unsubstituted organic acid radical, a substituted or unsubstituted alkyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted heteroaryl group, a substituted or unsubstituted aralkyl group, a substituted or unsubstituted heteroaralkyl group, a substituted or unsubstituted cycloalkyl group, a substituted or unsubstituted heterocycloalkyl group, a substituted or unsubstituted cycloalkylalkyl, a substituted or unsubstituted heterocycloalkylalkyl, a sugar or a protecting group.
    Type: Grant
    Filed: May 26, 2000
    Date of Patent: April 1, 2003
    Assignee: Pharma-Eco Laboratories, Inc.
    Inventors: Salah Zahr, David A. Swanson, Adel M. Moussa, Luning Han
  • Substitute 11-phenyl-dibenzazepine compounds useful for the treatment or prevention of diseases characterized by abnormal cell proliferation
    Patent number: 6534497
    Abstract: The present invention provides substituted 11-phenyl-dibenzazepine compounds that are specific, potent and safe inhibitors of mammalian cell proliferation. The compounds can be used to inhibit mammalian cell proliferation in situ as a therapeutic approach towards the treatment or prevention of diseases characterized by abnormal cell proliferation, such as cancer.
    Type: Grant
    Filed: September 22, 2000
    Date of Patent: March 18, 2003
    Assignees: Nuchem Pharmaceuticals, Inc., Children's Medical Center Corporation, Presidents and Fellows of Harvard College
    Inventors: Carlo Brugnara, Jose Halperin, Rudolf Fluckiger, Emile M. Bellott, Jr., Richard John Lombardy, John J. Clifford, Ying-Duo Gao, Reem M. Haidar, Eugene W. Kelleher, Adel M. Moussa, Yesh P. Sachdeva, Minghua Sun, Heather N. Taft, Michael H. Zeldin
  • Synthesis of nitroalcohol diastereomers
    Publication number: 20030040644
    Abstract: The present invention relates to a method of preparing a 1-nitro-3-substituted-3-amino-2-propanol diastereomer represented by Structural Formula I: 1
    Type: Application
    Filed: July 3, 2002
    Publication date: February 27, 2003
    Applicant: Pharm-Eco Laboratories, Inc.
    Inventors: Richard L. Gabriel, Adel M. Moussa, Sharon Fitzhenry, Changhua Liu, David A. Swanson, Brittany Le, Salah Zahr, Yesh P. Sachdeva, Jurjus Jurayj
  • Substituted diphenyl indanone, indane and indole compounds and analogues thereof useful for the treatment of prevention of diseases characterized by abnormal cell proliferation
    Publication number: 20020198188
    Abstract: The present invention provides substituted 3,3-diphenyl indanone, indane and indole compounds, as well as analogues thereof, which are specific, potent and safe inhibitors of mammalian cell proliferation. The compounds can be used to inhibit mammalian cell proliferation in situ as a therapeutic approach towards the treatment or prevention of diseases characterized by abnormal cell proliferation, such as cancer.
    Type: Application
    Filed: January 10, 2002
    Publication date: December 26, 2002
    Applicant: Children's Medical Center Corporation
    Inventors: Carlo Brugnara, Jose Halperin, Rudolf Fluckiger, Emile M. Bellott, Richard John Lombardy, John J. Clifford, Ying-Duo Gao, Reem M. Haidar, Eugene W. Kelleher, Adel M. Moussa, Yesh P. Sachdeva, Minghua Sun, Heather N. Taft